Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.
Provider: Pechala's Reports
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Oxygen Biotherapeutics Inc prices $52 mln underwritten offering

Tuesday, 18 Mar 2014 08:45am EDT 

Oxygen Biotherapeutics Inc:Prices underwritten public offering of shares of common stock at a public offering price of $5.60 per share for gross proceeds of about $52 mln, prior to deducting underwriting discounts and commissions and offering expenses payable by the company.Grants underwriters a 45-day option to purchase up to an additional 1,392,857 shares of common stock to cover over-allotments, if any.Intends to use the net proceeds received from the offering for furthering its clinical trials and efforts to obtain regulatory approval for Levosimendan and Oxycyte, developing its other product candidates, supporting manufacturing of Levosimendan and Oxycyte and general corporate purposes.Offering is expected to close on or about March 21, 2014, subject to satisfaction of customary closing conditions.Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc is acting as the sole book-running manager in connection with the offering.MTS Securities, LLC, an affiliate of MTS Health Partners, LP, is acting as the co-manager for the offering. 

Company Quote

-0.03 -0.75%
22 Jul 2014